GoodRx (NASDAQ:GDRX) Stock Price Up 2% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price was up 2% during mid-day trading on Friday . The stock traded as high as $4.64 and last traded at $4.61. Approximately 294,790 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 1,417,572 shares. The stock had previously closed at $4.52.

Analyst Ratings Changes

Several analysts recently commented on the company. Mizuho began coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. Morgan Stanley reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Citigroup dropped their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.37.

GoodRx Trading Up 2.2 %

The stock has a market cap of $1.76 billion, a P/E ratio of -154.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm’s fifty day simple moving average is $5.09 and its 200-day simple moving average is $6.82.

Hedge Funds Weigh In On GoodRx

Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of GoodRx by 358.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock valued at $169,000 after purchasing an additional 18,997 shares during the period. Franklin Resources Inc. bought a new stake in GoodRx in the third quarter worth approximately $5,675,000. Sanctuary Advisors LLC bought a new stake in GoodRx in the third quarter worth approximately $85,000. Barclays PLC lifted its stake in GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the period. Finally, Fortem Financial Group LLC bought a new position in shares of GoodRx during the 3rd quarter worth approximately $772,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.